LEXICON PHARMACEUTICALS, INC. (LXRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q3 '21: 483K Q4 '21: 298K Q1 '22: 308K Q2 '22: 109K Q3 '22: 125K Q4 '22: 139K Q1 '23: 126K Q2 '23: 408K Q3 '23: 531K Q4 '23: 1.2M Q1 '24: 2.3M Q2 '24: 3.6M Q3 '24: 5.2M Q4 '24: 31.1M Q1 '25: 31.2M Q2 '25: 58.4M Q3 '25: 70.9M Q4 '25: 49.8M Q1 '26: 69.6M Q2 '26: 41.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 25M 50M 75M Q3 '21: 483K Q4 '21: 298K Q1 '22: 308K Q2 '22: 109K Q3 '22: 125K Q4 '22: 139K Q1 '23: 126K Q2 '23: 400K Q3 '23: 516K Q4 '23: 1.1M Q1 '24: 2.2M Q2 '24: 3.4M Q3 '24: 4.9M Q4 '24: 30.5M Q1 '25: 30.6M Q2 '25: 58M Q3 '25: 70.4M Q4 '25: 49.5M Q1 '26: 69.3M Q2 '26: 41.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -69.2M Q4 '21: -87.1M Q1 '22: -89.6M Q2 '22: -95.7M Q3 '22: -95.8M Q4 '22: -100.8M Q1 '23: -108.5M Q2 '23: -128.8M Q3 '23: -155.3M Q4 '23: -171.8M Q1 '24: -185.9M Q2 '24: -197.1M Q3 '24: -211.1M Q4 '24: -197.1M Q1 '25: -177.5M Q2 '25: -118.4M Q3 '25: -66.9M Q4 '25: -48.9M Q1 '26: -24.2M Q2 '26: -54.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -67.6M Q4 '21: -87.8M Q1 '22: -90.3M Q2 '22: -96.8M Q3 '22: -97.1M Q4 '22: -101.9M Q1 '23: -110.4M Q2 '23: -130.7M Q3 '23: -157.9M Q4 '23: -177.1M Q1 '24: -193.6M Q2 '24: -202.1M Q3 '24: -216.4M Q4 '24: -200.4M Q1 '25: -177.3M Q2 '25: -120.6M Q3 '25: -68.6M Q4 '25: -50.3M Q1 '26: -26.1M Q2 '26: -61.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 250K 500K 750K Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 8K Q3 '23: 15K Q4 '23: 85K Q1 '24: 116K Q2 '24: 274K Q3 '24: 338K Q4 '24: 616K Q1 '25: 615K Q2 '25: 482K Q3 '25: 421K Q4 '25: 274K Q1 '26: 352K Q2 '26: 358K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -98.4M Q4 '21: -87M Q1 '22: -85.3M Q2 '22: -87.8M Q3 '22: -90.1M Q4 '22: -88.9M Q1 '23: -97M Q2 '23: -110.7M Q3 '23: -132.9M Q4 '23: -161.9M Q1 '24: -185.4M Q2 '24: -195.8M Q3 '24: -207.8M Q4 '24: -178.8M Q1 '25: -167.4M Q2 '25: -101.9M Q3 '25: -72.1M Q4 '25: -67.9M Q1 '26: -38.8M Q2 '26: -65M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q1 '20: 117.4M Q2 '20: 98M Q3 '20: -133.1M Q4 '20: -143.1M Q1 '21: -146.2M Q2 '21: -122.7M Q3 '21: -99.7M Q4 '21: -88.2M Q1 '22: -86.5M Q2 '22: -88.1M Q3 '22: -90.2M Q4 '22: -90.2M Q1 '23: -98.5M Q2 '23: -112.4M Q3 '23: -134.6M Q4 '23: -162.4M Q1 '24: -185.6M Q2 '24: -196.2M Q3 '24: -208.4M Q4 '24: -179.8M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '20: 106.5M Q2 '20: 107.1M Q3 '20: 117.6M Q1 '21: 143.4M Q2 '21: 144.5M Q3 '21: 145.8M Q1 '22: 149.2M Q2 '22: 149.6M Q3 '22: 174.9M Q1 '23: 189M Q2 '23: 204.8M Q3 '23: 244.9M Q1 '24: 245.4M Q2 '24: 310.8M Q3 '24: 361.5M Q1 '25: 362.1M Q2 '25: 363.6M Q3 '25: 363.4M Q1 '26: 400.2M Q2 '26: 437.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.90 -0.60 -0.30 0.00 0.30 0.60 0.90 Q3 '21: -0.47 Q4 '21: -0.61 Q1 '22: -0.62 Q2 '22: -0.65 Q3 '22: -0.62 Q4 '22: -0.62 Q1 '23: -0.63 Q2 '23: -0.69 Q3 '23: -0.77 Q4 '23: -0.80 Q1 '24: -0.83 Q2 '24: -0.78 Q3 '24: -0.75 Q4 '24: -0.64 Q1 '25: -0.51 Q2 '25: -0.33 Q3 '25: -0.19 Q4 '25: -0.14 Q1 '26: -0.07 Q2 '26: -0.15 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.